-
Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor.
Scientific reports 20140101
-
Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.
The Tohoku journal of experimental medicine 20121201
-
Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
The American journal of medicine 20121001
-
The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Diabetes & vascular disease research 20121001
-
Association of changes in ambulatory arterial stiffness index and pulse wave velocity during antihypertensive treatment: the J-CORE study.
American journal of hypertension 20120801
-
Azelnidipine, unique calcium channel blocker could prevent stress-induced cardiac dysfunction like α·β blocker.
Journal of cardiology 20120701
-
Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
Hypertension (Dallas, Tex. : 1979) 20120601
-
Calcium antagonist added to angiotensin receptor blocker: a recipe for reducing blood pressure variability?: evidence from day-by-day home blood pressure monitoring.
Hypertension (Dallas, Tex. : 1979) 20120601
-
Mechanistic study on degradation of azelnidipine solution under radical initiator-based oxidative conditions.
Journal of pharmaceutical and biomedical analysis 20120305
-
Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity.
Hypertension research : official journal of the Japanese Society of Hypertension 20120301
-
Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence.
British journal of pharmacology 20120201
-
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
Bioorganic & medicinal chemistry letters 20120115
-
Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.
Journal of nephrology 20120101
-
Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.
Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101
-
Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney disease: a randomized controlled study.
American journal of nephrology 20120101
-
Solid state characterizations and analysis of stability in azelnidipine polymorphs.
Chemical & pharmaceutical bulletin 20120101
-
Azelnidipine inhibits Msx2-dependent osteogenic differentiation and matrix mineralization of vascular smooth muscle cells.
International heart journal 20120101
-
Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria.
Cardiovascular drugs and therapy 20110801
-
Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Hypertension research : official journal of the Japanese Society of Hypertension 20110801
-
L-/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers.
Hypertension research : official journal of the Japanese Society of Hypertension 20110801
-
Azelnidipine, a new calcium channel blocker, promotes skin wound healing in diabetic rats.
The Journal of surgical research 20110701
-
Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease.
Clinical cardiology 20110601
-
Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker.
American journal of hypertension 20110401
-
Reduction of albuminuria with antihypertensive treatment: is more always better?
American journal of hypertension 20110401
-
Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: the J-CORE study.
Atherosclerosis 20110301
-
Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property.
International journal of cardiology 20110121
-
Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats.
Kidney & blood pressure research 20110101
-
Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J).
Circulation journal : official journal of the Japanese Circulation Society 20110101
-
Comparative effects of azelnidipine and amlodipine on myocardial function and mortality after ischemia/reperfusion in dogs.
Journal of pharmacological sciences 20110101
-
Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study.
Vascular health and risk management 20110101
-
Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function--a crossover trial (AGENT).
Cardiovascular diabetology 20110101
-
Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis.
Cardiovascular diabetology 20110101
-
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
Bioorganic & medicinal chemistry 20101115
-
Azelnidipine-induced chyloperitoneum in a patient with microscopic polyangiitis.
Clinical and experimental nephrology 20101001
-
Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients.
The American journal of the medical sciences 20100501
-
Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
Clinical therapeutics 20100501
-
Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice.
Circulation journal : official journal of the Japanese Circulation Society 20100401
-
Cardiovascular effects of azelnidipine in comparison with those of amlodipine assessed in the halothane-anaesthetized dog.
Basic & clinical pharmacology & toxicology 20100201
-
[Enantiomeric separation of azelnidipine by high performance liquid chromatography with chiral stationary phase].
Se pu = Chinese journal of chromatography 20100201
-
Azelnidipine, a long-acting calcium channel blocker, could control hypertension without decreasing cerebral blood flow in post-ischemic stroke patients. A 123I-IMP SPECT follow-up study.
Hypertension research : official journal of the Japanese Society of Hypertension 20100101
-
[Calcium antagonists: current and future applications based on new evidence. Calcium channel blockers and autonomic nervous system].
Clinical calcium 20100101
-
Beneficial effect of combination therapy comprising angiotensin II receptor blocker plus calcium channel blocker on plasma adiponectin levels.
Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101
-
Plasma renin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine, in hypertensive patients.
Internal medicine (Tokyo, Japan) 20100101
-
Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker.
Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101
-
Cytokine reducing effect of azelnidipine in human peripheral blood mononuclear cells.
Biological & pharmaceutical bulletin 20100101
-
Azelnidipine and amlodipine: a comparison of their effects and safety in a randomized double-blinded clinical trial in Chinese essential hypertensive patients.
Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101
-
Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage.
Cardiovascular diabetology 20100101
-
Azelnidipine exerts renoprotective effects by improvement of renal microcirculation in angiotensin II infusion rats.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20091201
-
A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study.
Hypertension research : official journal of the Japanese Society of Hypertension 20091201
-
Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
Hypertension research : official journal of the Japanese Society of Hypertension 20091101
-
Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
Hypertension (Dallas, Tex. : 1979) 20091001
-
Central blood pressure under angiotensin and calcium channel blockade.
Hypertension (Dallas, Tex. : 1979) 20091001
-
Impact of azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction: multi-center study with echocardiography.
Hypertension research : official journal of the Japanese Society of Hypertension 20091001
-
Combination of chronic exercise and antihypertensive therapy enhances renoprotective effects in rats with renal ablation.
American journal of hypertension 20091001
-
Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo university (ALPS-J).
Cardiovascular drugs and therapy 20091001
-
Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats.
Journal of hypertension 20090901
-
Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers.
Journal of cardiovascular pharmacology 20090701
-
Combination use of immune complexes and a Ca2(+) channel blocker azelnidipine enhances interleukin-12 p40 secretion without T helper type 17 cytokine secretion in human monocyte-derived dendritic cells.
Clinical and experimental immunology 20090601
-
Therapeutic strategy for ischemic stroke.
Neurochemical research 20090401
-
Chronotropic effects of azelnidipine, a slow- and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: a comparison with amlodipine.
Journal of cardiovascular pharmacology 20090401
-
Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R.
European journal of pharmacology 20090301
-
Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists.
American journal of hypertension 20090201
-
Comparative effects of olmesartan and azelnidipine on atrial structural remodeling in spontaneously hypertensive rats.
Pharmacology 20090101
-
Gene and stem cell therapy in ischemic stroke.
Cell transplantation 20090101
-
Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis.
Drug metabolism and pharmacokinetics 20090101
-
Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys.
Kidney & blood pressure research 20090101
-
Azelnidipine decreases plasma matrix metalloproteinase-9 levels after endovascular abdominal aortic aneurysm repair.
The Kurume medical journal 20090101
-
Enhanced pulsatile pressure accelerates vascular smooth muscle migration: implications for atherogenesis of hypertension.
Cardiovascular research 20081201
-
Renoprotective effect of azelnidipine in rats.
Biological & pharmaceutical bulletin 20081201
-
Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
Journal of cardiovascular pharmacology 20081201
-
Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.
Hypertension research : official journal of the Japanese Society of Hypertension 20081201
-
Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.
Clinical nephrology 20081101
-
Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers.
Die Pharmazie 20080801
-
In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study.
Hypertension research : official journal of the Japanese Society of Hypertension 20080801
-
In vivo imaging of renal redox status during azelnidipine treatment.
Hypertension research : official journal of the Japanese Society of Hypertension 20080801
-
Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.
Hypertension research : official journal of the Japanese Society of Hypertension 20080601
-
Effects of azelnidipine on the autonomic functions and its influence on arterial stiffness and endothelial functions.
Journal of cardiology 20080401
-
Spectroscopic studies on the interaction of azelnidipine with bovine serum albumin.
International journal of pharmaceutics 20080303
-
Effects of antihypertensive drugs and exercise training on insulin sensitivity in spontaneously hypertensive rats.
Hypertension research : official journal of the Japanese Society of Hypertension 20080301
-
Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice.
Atherosclerosis 20080101
-
Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure.
Endocrine journal 20071201
-
Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats.
Brain research 20071024
-
Antioxidative effects of azelnidipine on mesangial cell proliferation induced by highly concentrated insulin.
European journal of pharmacology 20070719
-
Enantioselective determination of azelnidipine in human plasma using liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070601
-
Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
The American journal of the medical sciences 20070601
-
Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure.
Journal of cardiovascular pharmacology 20070601
-
Effect of benidipine on simvastatin metabolism in human liver microsomes.
Drug metabolism and pharmacokinetics 20070601
-
The long-acting Ca2+-channel blocker azelnidipine prevents left ventricular remodeling after myocardial infarction.
Journal of pharmacological sciences 20070401
-
Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats.
Hypertension research : official journal of the Japanese Society of Hypertension 20070401
-
Azelnidipine inhibits H2O2-induced cell death in neonatal rat cardiomyocytes.
Cardiovascular drugs and therapy 20070201
-
Determination of azelnidipine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry.
Journal of pharmaceutical and biomedical analysis 20070117
-
Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity.
Clinical and experimental hypertension (New York, N.Y. : 1993) 20070101
-
Effects of calcium channel blocker azelnidipine on experimental abdominal aortic aneurysms.
Surgery today 20070101
-
Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity.
Arzneimittel-Forschung 20070101
-
SDF-1-induced adhesion of monocytes to vascular endothelium is modulated by azelnidipine via protein kinase C inhibition.
European journal of pharmacology 20061215
-
Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
The Journal of pharmacology and experimental therapeutics 20061201
-
Tilting-induced decrease in systolic blood pressure in bedridden hypertensive elderly inpatients: effects of azelnidipine.
Hypertension research : official journal of the Japanese Society of Hypertension 20061201
-
Simultaneous determination of azelnidipine and two metabolites in human plasma using liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20061121
-
The actions of azelnidipine, a dihydropyridine-derivative Ca antagonist, on voltage-dependent Ba2+ currents in guinea-pig vascular smooth muscle.
British journal of pharmacology 20061101
-
The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
Journal of hypertension 20061001
-
Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis.
Journal of hypertension 20061001
-
Azelnidipine down-regulates renal angiotensin-converting enzyme and mineralocorticoid receptor mRNA in diabetic hypertensive rats.
Journal of pharmacological sciences 20061001
-
Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine.
Hypertension research : official journal of the Japanese Society of Hypertension 20061001
-
Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species.
European journal of pharmacology 20060928
-
A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates.
Journal of hypertension 20060901
-
[Novel actions of calcium channel blockers].
Nihon rinsho. Japanese journal of clinical medicine 20060801
-
Effects of calcium channel blockade on angiotensin II-induced peritubular ischemia in rats.
The Journal of pharmacology and experimental therapeutics 20060301
-
Comparative effects of azelnidipine and other Ca2+-channel blockers on the induction of inducible nitric oxide synthase in vascular smooth muscle cells.
Journal of cardiovascular pharmacology 20060201
-
The newly developed calcium antagonist, azelnidipine, increases drain volume in continuous ambulatory peritoneal dialysis patients.
Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 20060101
-
Azelnidipine, a new long-acting calcium-channel blocker, inhibits tumour necrosis factor-alpha-induced monocyte chemoattractant protein-1 expression in endothelial cells.
The Journal of international medical research 20060101
-
Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats.
Hypertension research : official journal of the Japanese Society of Hypertension 20051201
-
Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
Journal of hypertension 20050701
-
Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells.
Molecular pharmacology 20050501
-
Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.
Medical hypotheses 20050101
-
Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (AGE)-injected rats.
International journal of tissue reactions 20050101
-
Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells.
Drugs under experimental and clinical research 20050101
-
Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model.
Hypertension research : official journal of the Japanese Society of Hypertension 20041001
-
Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties.
Journal of cardiovascular pharmacology 20040501
-
Biliary excretion of azelnidipine, a calcium antagonist, in rats.
Journal of gastroenterology and hepatology 20040401
-
Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.
Hypertension (Dallas, Tex. : 1979) 20040201
-
Antioxidant effect of a new calcium antagonist, azelnidipine, in cultured human arterial endothelial cells.
The Journal of international medical research 20040101
-
[Pharmacological profiles and clinical effects of azelnidipine, a long-acting calcium channel blocker].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20031201
-
Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure.
Hypertension research : official journal of the Japanese Society of Hypertension 20030301
-
Azelnidipine. CS 905, Calblock, RS 9054.
Drugs in R&D 20030101
-
Azelnidipine.
Drugs 20030101
-
Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist: beyond the renoprotective effects of ACE inhibitor monotherapy in a spontaneous hypertensive rat with renal ablation.
Hypertension research : official journal of the Japanese Society of Hypertension 20020501
-
Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker.
Japanese journal of pharmacology 19890901
